Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Rozlytrek"

NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a potent inhibitor of TRKA/B/C. In phase 1/2 studies ( ALKA, STARTRK ...

Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary analysis ( data cut-off: 31 May 2018 ) of patients with ROS1 fusion-positive ( ...